Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared AI breast cancer detection suite by iCAD (acquired by RadNet 2025). ProFound AI reads 40M+ mammograms globally with 23% improved detection rate.
Profound AI is the medical imaging AI brand developed by iCAD, a pioneer in cancer detection technology. iCAD's ProFound AI platform applies deep learning to mammography analysis, providing radiologists with AI-powered decision support that identifies suspicious lesions, calculates cancer risk scores, and prioritizes reading worklists based on AI-assessed urgency. The system is designed to function as a second reader — augmenting rather than replacing radiologist judgment — by flagging findings that warrant closer attention and reducing the cognitive load on radiologists reviewing high volumes of routine screening mammograms.\n\nProFound AI has achieved FDA clearance as a medical device for breast cancer detection, enabling its use in clinical radiology workflows across US health systems. The platform processes mammograms in real time, integrating with existing PACS and radiology information systems so it can be deployed without disrupting established workflow. Its clinical validation studies have demonstrated a 23% improvement in cancer detection rate compared to unassisted reads, while simultaneously reducing false positives — a combination that is clinically meaningful and commercially compelling for radiology practices seeking to improve outcomes without adding radiologist time.\n\nProFound AI reads over 40 million mammograms globally, making it one of the most widely deployed FDA-cleared AI systems in radiology. iCAD was acquired by RadNet in 2025, integrating ProFound into one of the largest radiology network operators in the United States. This acquisition significantly expands ProFound's deployment footprint, as RadNet operates hundreds of imaging centers across the US and has the scale to make AI-assisted mammography a standard-of-care offering. The combination of FDA clearance, proven clinical performance, massive global deployment, and integration into a major radiology network positions ProFound AI as a market-defining product in cancer detection AI.
$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model
CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.